T. E. Witzig

Articles by T. E. Witzig

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Leo I. Gordon, MD,G. A. Wiseman,S. Spies,C. Emmanouilides,Myron S. Czuczman, MD,I. W. Flinn,N. L. Barlett,J. L. Murray,B. Alkuzweny,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD,Christine A. White, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Christine A. White, MD,Leo I. Gordon, MD,J. L. Murray,G. A. Wiseman,C. Emmanouilides,Myron S. Czuczman, MD,D. Shen,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial

T. E. Witzig

Articles by T. E. Witzig

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

Latest Updated Articles

Trending on CancerNetwork

FDA Issues CRL for Dasatinib in CML/ALL

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer Care

Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease